Latest news for Pembangunan Perumahan (OTC:PTPPF) Stock

PT Pembangunan Perumahan (Persero) Tbk provides construction services. The company organizes itself into six segments: construction, property and realty, EPC (engineering, procurement, and construction), precast, equipment rent service, and energy. The construction segment, which generates the majority of the revenue, offers public construction services, including building airports, dams, railways, and other structures. In the other segments, the company creates and sells construction equipment and materials, develops and operates buildings, and works on projects in the energy, oil, gas, and mining sectors.

PT Pembangunan Perumahan (Persero) Tbk

Ohio is on the brink of finally opening its recreational cannabis market as 34 medical cannabis businesses, including growers, processors and testing labs have been granted permissions to expand into adult-use sales. This development marks a crucial step towards the state&#8217;s recreational <a href="http://benzinga.com/cannabis">cannabis</a> sales rollout nearly nine months after <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">voters approved recreational use</a>, with businesses poised for a surge in demand.
<h3 class="wp-block-heading">Recreational Dispensary Approvals Still Pending</h3>
However, sales have yet to commence due to pending approvals for dispensaries, <a href="https://www.ideastream.org/show/sound-of-ideas/2024-07-31/ohio-granting-permits-to-companies-for-recreational-marijuana-market">according</a> to Ideastream. The Ohio Division of Cannabis Control (DCC) aims to issue dual-use licenses to dispensaries by September 7. Jamie Crawford, a public information officer with the Ohio Department of Commerce, <a href="https://www.benzinga.com/markets/cannabis/24/07/39870999/ohios-adult-use-cannabis-market-takes-its-first-major-step">recently explained that the timing for sales would depend on each dispensary's readiness</a>, emphasizing that the state is ensuring that businesses meet all requirements for a safe and compliant market entry.
<h3 class="wp-block-heading">Key Players In Ohio Ramp Up Production</h3>
Meanwhile, key players like Riviera Creek, Pure Ohio Wellness and Green Thumb Industries Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) have already received dual-use certificates, ramping up production in anticipation of new market demands. This move comes as the <a href="https://www.benzinga.com/markets/cannabis/24/06/39144708/ohio-now-accepting-recreational-marijuana-applications-when-will-sales-begin-official-cant-circl">state processes numerous applications for dual-use operations</a>, reflecting a robust interest in the sector&#8217;s expansion.
Real Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/40045648/kamala-harris-gains-on-trump-in-his-home-state-of-florida-why-cannabis-legalization-and-abortion">Kamala Harris Gains On Trump In His Home State Of Florida: Why? Cannabis Legalization And Abortion Access</a>
<h3 class="wp-block-heading">House Bill 230 Sparks Controversy Over Cannabis Testing</h3>
Amidst these developments, legislative movements are also seeking to shape the landscape. House Bill 230, recently passed in the Ohio House, introduces new measures for addressing drug-related offenses, <a href="https://www.nbc4i.com/news/local-news/central-ohio-news/ohio-bill-would-allow-impaired-driving-test-for-marijuana-but-does-it-work/">reports</a> NBC4, including a controversial provision for oral fluid tests to identify impaired drivers, potentially including those under the influence of cannabis. Critics, including Dennis Cauchon of Harm Reduction Ohio, argue that these tests are not reliably indicative of impairment. &#8220;It sounds good and in certain cases, it makes a difference," Cauchon stated. "But in marijuana oral fluid testing, one isn't better than the other. None of them are very good.&#8221;
This skepticism is echoed in scientific circles, with studies suggesting that <a href="https://www.benzinga.com/markets/cannabis/24/04/38134128/detection-of-cannabis-in-bodily-fluids-not-correlated-with-driving-impairment-new-review-shows">the presence of cannabinoids in saliva or breath does not correlate directly with impairment levels</a>. This raises concerns about the accuracy of such tests, particularly as they risk false positives for people who have consumed non-psychoactive <a href="https://www.benzinga.com/topic/hemp">hemp-derived products</a>.
Ohio's legislative and operational maneuvers aim at setting the stage for a robust adult-use cannabis market <a href="https://www.benzinga.com/markets/cannabis/24/06/39241470/gop-senators-introduce-new-bill-with-changes-to-ohios-cannabis-initiative-as-retail-sales-loom">amid contentious debates on related public safety measures</a>.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39870999/ohios-adult-use-cannabis-market-takes-its-first-major-step">Ohio&#8217;s Adult-Use Cannabis Market Takes Its First Major Step</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/40055095/does-cannabis-affect-your-driving-university-of-colorado-researchers-find-out">Does Cannabis Affect Your Driving? University Of Colorado Researchers Find Out</a></li>
</ul>
Featured image created with AI tools.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.

Cannabis

Government

News

Regulations

GTBIF

Ohio Approves 34 Dispensaries As Recreational Sales Near, New Cannabis DUI Testing Bill Controversy

WIIM

CTVA

Corteva shares are trading lower after the company reported worse-than-expected Q2 revenue results.  Additionally, the company announced the retirement of CFO Dave Anderson.

Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.30) by 4.62 percent. The company reported quarterly sales of $621.657 million which missed the analyst consensus estimate of $639.483 million by 2.79 percent. This is a 2.55 percent increase over sales of $606.206 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

BALY

Ballys Q2 2024 GAAP EPS $(1.24) Beats $(1.30) Estimate, Sales $621.657M Miss $639.483M Estimate

CDNA

CareDx shares are trading higher after the company reported better-than-expected Q2 financial results.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpaycom.com%2F&amp;esheet=54102589&amp;newsitemid=20240731673591&amp;lan=en-US&amp;anchor=Paycom+Software%2C+Inc.+%28NYSE%3A+PAYC%29&amp;index=1&amp;md5=7814728bfc633be88caba6b39c33dc61">Paycom Software, Inc. (NYSE:</a><a href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) ("Paycom"), a leading provider of comprehensive, cloud-based human capital management software, announced today that its board of directors has increased and extended its ongoing stock repurchase plan, such that $1.5 billion is available for repurchases through Aug. 15, 2026. Prior to the increase, approximately $676 million was available for repurchases.

Buybacks

PAYC

Paycom Increases And Extends Stock Repurchase Plan, Such That $1.5B Is Available For Repurchases Through Aug. 15, 2026 (~$676M Was Available For Repurchases)

Green Brick Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRBK#NYSE">GRBK</a>) reported quarterly earnings of $2.32 per share which beat the analyst consensus estimate of $1.74 by 33.33 percent. This is a 42.33 percent increase over earnings of $1.63 per share from the same period last year. The company reported quarterly sales of $560.631 million which beat the analyst consensus estimate of $502.637 million by 11.54 percent. This is a 22.87 percent increase over sales of $456.289 million the same period last year.

GRBK

Green Brick Partners Q2 2024 GAAP EPS $2.32 Beats $1.74 Estimate, Sales $560.631M Beat $502.637M Estimate

Guidance

ERII

Energy Recovery Reaffirms FY Revenue Guidance $140M-$150M

However, reflecting the continued strength of operating cash flow,reiterates the midpoint of adjusted cash flow from operations&nbsp;guidance&nbsp;range of&nbsp;$900 million&nbsp;to&nbsp;$960 million.&nbsp;

Service Corporation Now Expects FY24 Adjusted EPS At Lower End Of Its Prior Guidance Range Of $3.50 - $3.80, Est $3.67

OFLX

Omega Flex Q2 Revenue $24.62M; EPS $0.45 Per Share

Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.07) by 3.74 percent. This is a 47.14 percent decrease over losses of $(0.70) per share from the same period last year.

BMEA

Biomea Fusion Q2 EPS $(1.03) Beats $(1.07) Estimate

ALKS

Alkami Sees Q3 Total Revenue $83.8M-$85.3M vs $84.78M Est., Sees FY24 Total Revenue $330.5M-$333.5M vs $331.67M Est.

American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) reported quarterly losses of $(3.36) per share which beat the analyst consensus estimate of $(3.90) by 13.85 percent. The company reported quarterly sales of $62.790 million which beat the analyst consensus estimate of $61.612 million by 1.91 percent. This is a 0.55 percent increase over sales of $62.447 million the same period last year.

AMWL

American Well Q2 2024 GAAP EPS $(3.36) Beats $(3.90) Estimate, Sales $62.790M Beat $61.612M Estimate

OCGN

Ocugen shares are trading lower after the company announced an underwritten public offering.

Grants Underwriter 30-Day Option To Purchase Additional 15% Shares; Offering Subject To Market And Other Conditions

Offerings

Ocugen Announces Underwritten Public Offering Of Common Stock; Size Not Disclosed

MDXG

MiMedx Group shares are trading lower after the company reported worse-than-expected Q2 sales results.

Contineum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, today announced encouraging preclinical data on PIPE-307,a potentially first-in-class M1 receptor antagonist in development for patients with relapse-remitting multiple sclerosis (RRMS), were published online in the peer-reviewed journal, Proceedings of the National Academy of Science (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pnas.org%2Flatest&amp;esheet=54101195&amp;newsitemid=20240729449836&amp;lan=en-US&amp;anchor=PNAS&amp;index=1&amp;md5=b498b1bf5f9b4cccb9c9fca40ef29660">PNAS</a>).
The published data provide early evidence that PIPE-307 is a potentially first-in-class, novel, small molecule, selective inhibitor of the muscarinic type 1 M1 receptor. The full manuscript is titled "Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis" .

Biotech

General

CTNM

Contineum Therapeutics Announces Publication Of Data In The Proceedings Of The National Academy Of Sciences On PIPE-307, Its M1 Receptor Selective Inhibitor For Relapse-Remitting Multiple Sclerosis

New Mountain Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) reported quarterly earnings of $0.36 per share which met the analyst consensus estimate. The company reported quarterly sales of $94.588 million which beat the analyst consensus estimate of $89.604 million by 5.56 percent. This is a 0.95 percent decrease over sales of $95.492 million the same period last year.

NMFC

New Mountain Finance Q2 2024 GAAP EPS $0.36, Inline, Sales $94.588M Beat $89.604M Estimate

Vermilion Energy Q2 Sales C$478.925M Miss C$515.750M Estimate

NCS Multistage Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCSM#NASDAQ">NCSM</a>) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.23) by 16.26 percent. This is a 58.8 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $29.69 million which beat the analyst consensus estimate of $28.50 million by 4.18 percent. This is a 16.93 percent increase over sales of $25.39 million the same period last year.

NCSM

NCS Multistage Holdings Q2 Adj $(1.03) Beats $(1.23) Estimate, Sales $29.69M Beat $28.50M Estimate

SDGR

Schrodinger shares are trading higher after the company reported better-than-expected Q2 financial results.

Pembangunan Perumahan

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Pembangunan Perumahan

News

Latest news for Pembangunan Perumahan (OTC:PTPPF) Stock